CRISPR Therapeutics
NEWS
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
CRISPR, the gene editing technique that promises designer babies, to end to all disease as we know it, and biohacking where individuals could change their own genome to include that of fluorescent jellyfish or lobster claws, seems to have more problems than originally thought.
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
Now, two studies published in Nature Medicine suggest that CRISPR may lead to cancer unintentionally.
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
JOBS
IN THE PRESS